BeyondSpring is trading at $0.72, down 6.88%, with no new company-specific announcement identified in available coverage to explain the September 30 decline.

  • BeyondSpring’s latest reported news was announced September 29: FDA Fast Track designation for plinabulin plus docetaxel and a China subsidiary transaction intended to support the DUBLIN-4 trial.
  • Available reporting does not establish that news as the cause of the current decline.
  • The provided major indices are modestly higher, so broad-market weakness does not explain the move.